General Overview

The FazaClo^® Patient Registry is part of a systematic active post-marketing surveillance program mandated by the United States Food and Drug Administration. Pursuant to this mandate, Azur Pharma is required to collect laboratory data, patient identification information and investigate adverse events associated with FazaClo^®.

The FazaClo Patient Registry:

• Provides a database for WBC and absolute neutrophil count monitoring of patients treated with FazaClo to permit early detection of clozapine-induced leukopenia.

• Provides confidential registration and report process for patients treated with FazaClo.

• Provides ongoing updating of the Clozapine National Non-Rechallenge Masterfile with patients treated with FazaClo who become non-rechallengeable.

The FazaClo Patient Registry under the direction of the FazaClo Patient Registry Coordinating Center, includes a registry team, a professional toll-free call center at 1-877-FAZACLO (329-2256), and a registry web-site.

The FazaClo Patient Registry team is composed of dedicated healthcare, registry, call center, administrative support and data management professionals.

The FazaClo Patient Registry Call Center is available 24 hours a day and 365 days a year to support all registry operations. Health care practitioners, pharmacist and patients may contact the call center with any questions related to the FazaClo Patient Registry. Health care practitioners and pharmacists may request registry materials directly through the call center.

Click here to order a Registry Packet